Elevated first trimester PAPP-A is associated with increased risk of placenta accreta

Prenatal Diagnosis

Volumn 34, Issue 2, 2014, Pages 159-162

  Desai, N ^a   Krantz, D ^b   Roman, A ^a   Fleischer, A ^a   Boulis, S ^a   Rochelson, B ^a  

^a DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^b PERKINELMER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHORIONIC GONADOTROPIN BETA SUBUNIT; PAPPA1 PROTEIN, HUMAN; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; COHORT ANALYSIS; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; METABOLISM; PLACENTA ACCRETA; PREGNANCY; RETROSPECTIVE STUDY; YOUNG ADULT;

ADULT; BIOMARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; COHORT STUDIES; FEMALE; HUMANS; PLACENTA ACCRETA; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84895070855     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4277     Document Type: Article

References (20)

1. Silver RM, Landon MB, Rouse DJ, et al. Maternal morbidity associated with multiple repeat cesarean deliveries. Obstet Gynecol 2006;107(6):1226-32.
2. Timor-Tritsch IE, Monteagudo A. Unforeseen consequences of the increasing rate of cesarean deliveries: early placenta accreta and cesarean scar pregnancy. A Review. Am J Obstet Gynecol 2012;207(1):14-29.
3. Publications Committee SfM-FM, Belfort MA. Placenta accreta. Am J Obstet Gynecol 2010;203(5):430-9.
4. Warshak CR, Ramos GA, Eskander R, et al. Effect of predelivery diagnosis in 99 consecutive cases of placenta accreta. Obstet Gynecol 2010;115(1):65-9.
5. Wright JD, Herzog TJ, Shah M, et al. Regionalization of care for obstetric hemorrhage and its effect on maternal mortality. Obstet Gynecol 2010; 115(6):1194-200.
6. Briery CM, Rose CH, Hudson WT, et al. Planned vs emergent cesarean hysterectomy. Am J Obstet Gynecol 2007;197(2):154 e1-5.
7. Eller AG, Bennett MA, Sharshiner M, et al. Maternal morbidity in cases of placenta accreta managed by a multidisciplinary care team compared with standard obstetric care. Obstet Gynecol 2011;117(2 Pt 1):331-7.
8. Yaron Y, Cherry M, Kramer RL, et al. Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 1999;181(4):968-74.
9. Krantz D, Goetzl L, Simpson JL, et al. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol 2004;191(4):1452-8.
10. Zelop C, Nadel A, Frigoletto FD, Jr., et al. Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein. Obstet Gynecol 1992;80(4):693-4.
11. Kupferminc MJ, Tamura RK, Wigton TR, et al. Placenta accreta is associated with elevated maternal serum alpha-fetoprotein. Obstet Gynecol 1993;82(2):266-9.
12. Hung TH, Shau WY, Hsieh CC, et al. Risk factors for placenta accreta. Obstet Gynecol 1999;93(4):545-50.
13. Dreux S, Salomon LJ, Muller F, et al. Second-trimester maternal serum markers and placenta accreta. Prenat Diagn 2012;32(10):1010-2.
14. Krantz D, Hallahan T, Ravens R, et al. First trimester Down syndrome screening with dried blood spots using a dual analyte free beta hCG and PAPP-A immunofluorometric assay. Prenat Diagn 2011;31(9):869-74.
15. Comstock CH, Love JJ, Jr., Bronsteen RA, et al. Sonographic detection of placenta accreta in the second and third trimesters of pregnancy. Am J Obstet Gynecol 2004;190(4):1135-40.
16. Warshak CR, Eskander R, Hull AD, et al. Accuracy of ultrasonography and magnetic resonance imaging in the diagnosis of placenta accreta. Obstet Gynecol 2006;108(3 Pt 1):573-81.
17. Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004;191(4):1446-51.
18. Stirnemann JJ, Mousty E, Chalouhi G, et al. Screening for placenta accreta at 11-14weeks of gestation. Am J Obstet Gynecol 2011; 205(6):547 e1-6.
19. Khong TY. The pathology of placenta accreta, a worldwide epidemic. J Clin Path 2008;61(12):1243-6.
20. Pijnenborg R, Dixon G, Robertson WB, Brosens I. Trophoblastic invasion of human decidua from 8 to 18weeks of pregnancy. Placenta 1980;1(1):3-19.